The landscape of modern medicine is undergoing a paradigm shift, with targeted protein degradation (TPD) emerging as one of the most revolutionary therapeutic strategies in recent years. Forecasts indicate that the global Targeted Protein Degradation market will grow at a remarkable compound annual growth rate (CAGR) of 21.2% between 2025 and 2035, reaching an estimated USD 3,468.42 million by 2035. This marks a significant leap from its projected market value of USD 546.63 million in 2025.
What Is Targeted Protein Degradation?
Targeted protein degradation represents a novel approach in drug development that leverages the body’s innate protein disposal systems to selectively eliminate disease-causing proteins. Unlike traditional therapies that inhibit the activity of proteins, TPD technologies—such as PROTACs (Proteolysis-Targeting Chimeras), molecular glues, and LYTACs (Lysosome-Targeting Chimeras)—completely degrade the target proteins, offering more durable and effective treatment outcomes.
Request Sample Copy: https://wemarketresearch.c...
What Is Targeted Protein Degradation?
Targeted protein degradation represents a novel approach in drug development that leverages the body’s innate protein disposal systems to selectively eliminate disease-causing proteins. Unlike traditional therapies that inhibit the activity of proteins, TPD technologies—such as PROTACs (Proteolysis-Targeting Chimeras), molecular glues, and LYTACs (Lysosome-Targeting Chimeras)—completely degrade the target proteins, offering more durable and effective treatment outcomes.
Request Sample Copy: https://wemarketresearch.c...
09:37 AM - Apr 25, 2025 (UTC)
